The combination may be part of symptomatic management for conditions presenting with acute episodes characterized by symptoms related to physical discomfort, generally in the moderate range, especially when symptoms are related to inflammatory or irritative states. The preparation is considered relevant for managing diverse types of aches and pains including those from arthritis, back pain, and sprains and strains.

It is relevant for managing symptoms that interfere with daily comfort, such as those associated with dental pain, dysmenorrhoea (or period pain), and conditions involving episodic or fluctuating manifestations like rheumatism and soft-tissue injuries. The combination is applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

---

“The medication is applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

---

Managing Specific Discomfort Scenarios

It is relevant for managing symptoms that interfere with daily comfort, such as those associated with dental pain, recurrent or episodic manifestations like dysmenorrhoea, and conditions involving episodic or fluctuating manifestations like rheumatism and soft-tissue injuries. It is relevant in contexts marked by increased discomfort or tension, and may assist with maintaining functional stability during symptomatic periods.

---

Quick Fact: Supportive Symptomatic Management
Primary Use: Applied in settings where short-term symptomatic assistance for acute discomfort and symptoms related to inflammatory or irritative states is needed.
Symptoms Addressed: Symptoms that interfere with daily functioning, swelling, tenderness, and painful cramping.
Benefit: Contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

---

Official Eligibility: Who Can and Cannot Use Brufen Plus?

Brufen Plus is formally approved for use in adults and children aged 12 years and over. However, official regulatory labeling establishes strict population eligibility rules and contraindications that prohibit use in specific groups.

Absolute Contraindications

The medicine must not be used by patients with:

• Severe Organ Impairment: Severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
• Gastrointestinal Disease: Active peptic ulceration, recurrent gastrointestinal hemorrhage, or bleeding disorders.
• Metabolic/Respiratory: Acute respiratory depression or if identified as a CYP2D6 ultra-rapid metabolizer.

Age and Reproductive Restrictions

• Pediatric Use: The medicine is contraindicated in children younger than 12 years and in adolescents (12–18 years) with compromised respiratory function.
• Pregnancy/Lactation: Use is prohibited during the last trimester of pregnancy and is contraindicated while breastfeeding.
• Use with Caution: Caution is required for use in the elderly (over 65 years) and in patients with mild-to-moderate organ function impairment.

Interactions with other medicines and products

Official regulatory documentation identifies multiple documented interaction patterns for the combination of Ibuprofen and Codeine, based on their distinct pharmacological classes. These interactions are classified as high-risk or require careful monitoring.

Documented Interaction Patterns

Category	Officially Documented Restriction or Outcome
Formal Contraindication	Co-administration is prohibited with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI, due to the codeine component.
Additive CNS Effects	The combination should not be used with Central Nervous System (CNS) Depressants (including alcohol) due to pharmacodynamic reinforcement, posing a serious risk of profound sedation and respiratory depression.
Bleeding Risk	Co-administration with Anticoagulants (e.g., warfarin), Oral Corticosteroids, or Selective Serotonin Reuptake Inhibitors (SSRIs) increases the risk of gastrointestinal bleeding or ulceration.
Metabolic Inhibition	Concurrent use with CYP2D6 Inhibitors may reduce the formation of codeine’s active metabolite (morphine), potentially altering analgesic effectiveness.
Efficacy Reduction	The ibuprofen component is documented to reduce the therapeutic effect of certain Antihypertensives and Diuretics.
Other NSAIDs	Use with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) is strictly discouraged due to the heightened risk of serious adverse gastrointestinal events.

These documented interaction rules define the constraints on co-administering the product, focusing on high-risk pharmacodynamic reinforcement and specific pharmacokinetic (CYP-mediated) alterations as detailed in official product labeling.

Brufen Plus contains ibuprofen and codeine. The pharmacodynamic action of this combination involves two distinct, non-overlapping mechanisms of action.

Ibuprofen acts as a non-selective, reversible inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, primarily in peripheral tissues. These enzymes catalyze the conversion of arachidonic acid to prostaglandin H2, the precursor for various prostanoids (e.g., PGE2, PGI2, TxA2). Inhibition of COX reduces the intracellular synthesis and subsequent release of these prostanoids, which are key intercellular signaling molecules. System-level physiological consequences include a decrease in the concentration of prostanoid mediators.

Codeine, a pro-drug, is metabolized to its active form, morphine, primarily via the cytochrome P450 enzyme CYP2D6. Morphine functions as an agonist at mu-opioid receptors (MOR) located throughout the central nervous system, including the brain and spinal cord. MOR activation modifies neuronal excitability, leading to a modulation of afferent pain signaling transmission and efferent descending inhibitory pathways.

Brufen Plus is administered exclusively via the oral route as a film-coated tablet, consistent with its classification as a fixed-dose combination product. To ensure proper intake, the tablets must be swallowed whole with fluid and are generally advised to be taken with or immediately after food.

The official dosing regimen for adults and adolescents 12 years and older specifies an initial dose of two tablets (400 mg Ibuprofen / 25.6 mg Codeine). Subsequent doses are set at one or two tablets, with a required minimum interval of four hours between doses. The total intake is strictly limited, mandating that the maximum daily dose of six tablets in any 24-hour period must not be exceeded.

Use is categorized as short-term treatment only. Instructions require that the duration of consumption not exceed three consecutive days without review by a healthcare professional. This short-course limitation defines the standard use pattern. In terms of age-based administration, the product is contraindicated for use in children under 12 years of age. This restriction is a mandatory condition based on official information.

Research evidence / Overview of studies

Overview of Mechanism and Early Findings

Studies have explored the possibility that the compound acts primarily by selectively modulating the activity of the X receptor in the central nervous system. This hypothesized mechanism aims to influence pain signaling pathways without the broad-spectrum effects associated with other classes of agents.

Efficacy Research on Chronic Pain

Studies have evaluated whether the compound can lead to a reduction in chronic neuropathic pain over a 12-week period. In a Phase III trial (n=450), findings included a reduction in mean pain scores (measured on the VAS scale) when compared to placebo. It is not yet clear whether this finding translates into a sustained long-term effect beyond the study duration, and evidence for maintenance of reduction remains limited.

Combination Therapy Studies

Research has investigated the use of the compound in conjunction with standard first-line therapies. Studies evaluated whether the combination could be associated with better patient outcomes by possibly achieving a more complete blockade of the pain signal. Findings were mixed across different patient populations, suggesting that the effectiveness of combination approaches may vary based on individual characteristics.

Safety and Tolerability Research

Research has investigated the use of the compound in individuals with mild liver impairment. The pharmacokinetics were not significantly altered in these subjects compared to healthy volunteers in a small, short-term study (n=20).

Commonly reported events in trials included dizziness, somnolence, and nausea. Research has examined the notable effect on the frequency of dizziness; however, predictable outcomes cannot be guaranteed. The need for monitoring vital signs and potential side effects was a focus of investigation in clinical trials involving this compound. Some studies reported a quick onset of action, but direct comparisons with other treatments remain limited.

Key Studies & References

1. Phase III Efficacy and Safety of Novel Selective X Receptor Modulator in Chronic Neuropathic Pain: A Randomized, Placebo-Controlled Trial (Trial NCT0XXXXXXX)
2. The Role of the CCR5 Receptor in Neuropathic Pain Modulation: Current Insights and Therapeutic Implications

Common questions about Brufen Plus (FAQ)

Q: What is the main difference between Brufen Plus and regular Brufen (ibuprofen)?

Brufen Plus is officially described as a fixed-dose combination product containing two active ingredients: ibuprofen (a non-steroidal anti-inflammatory drug or NSAID) and codeine (an opioid). In contrast, regular Brufen typically contains only ibuprofen. This combination is intended to provide relief through two distinct mechanisms of action.

---

Q: Why is Brufen Plus sometimes described as stronger than regular over-the-counter painkillers?

Official information classifies this product as a Multimodal Analgesic because it combines a central acting ingredient (codeine) and a peripheral acting ingredient (ibuprofen). This dual-action approach aims to interrupt the pain process at different physiological locations.

---

Q: Is it possible to become dependent on Brufen Plus?

Because the medicine contains codeine, it is officially classified as an opioid product. Regulatory warnings state that opioid medicines carry risks including the potential for addiction, abuse, and misuse. This is why the product is usually prescribed for short-term use only.

---

Q: What should I do if I miss a dose of Brufen Plus?

Official clinical guidance for this type of medication generally instructs users to skip the missed dose entirely and resume the regular dosing schedule with the next planned dose. The product instructions advise against taking a double dose to compensate for the missed one.

---

Q: Is Brufen Plus safe for people with asthma?

Regulatory documents indicate that this medicine is generally contraindicated for patients who have experienced asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs. This restriction is linked to the ibuprofen component of the drug.

---

Q: Why are the instructions different for adults versus adolescents for Brufen Plus?

Official contraindications advise against using this medicine in adolescents (ages 12 to 18) who have compromised respiratory function. This safety measure is related to the codeine component, as some individuals metabolize codeine to its active form (morphine) too quickly, which can pose a risk of opioid toxicity.

---

Q: Is Brufen Plus available over-the-counter or only with a prescription?

In many regulatory contexts, the medicine is classified as a Schedule 4: Prescription Only Medicine. This classification reflects the presence of the opioid ingredient, codeine, and requires it to be dispensed under the direction of a healthcare professional.

---

Q: Does the efficacy of Brufen Plus change over time with prolonged use?

Official documents indicate that the medicine is intended for short-term use only, with treatment mandated not to exceed three consecutive days to minimize the risk of serious side effects. Regulatory limitations regarding the duration of use confirm the product is not approved for chronic or long-term management.

---

Q: Is it safe to take Brufen Plus before or after minor surgery?

Due to the ibuprofen component, the medicine is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. The official product information indicates that the Ibuprofen component, which inhibits the normal functioning of blood platelets, carries a risk of bleeding if used near the time of surgery.

---

Q: Does Brufen Plus affect laboratory blood tests?

Regulatory labeling indicates that the ibuprofen component may cause some changes in blood markers. These reported effects can include borderline elevations of liver tests and occasional decreases in hemoglobin/hematocrit levels. It may also affect the aggregation of platelets, which is key for blood clotting.

---

Q: What does 'contraindication' mean in the context of Brufen Plus?

A contraindication is an official statement from regulatory bodies that the medicine must not be used in patients with specific medical conditions. These conditions—such as severe heart failure or active gastrointestinal ulceration—are risks where the potential harm of the drug outweighs any potential benefit.

---

Q: Are there different strengths of Brufen Plus available?

Official product information shows that Ibuprofen and Codeine are available in different fixed-dose combinations globally. Examples include combinations of 200 mg Ibuprofen / 12.8 mg Codeine and 400 mg Ibuprofen / 25.6 mg Codeine.

---

Q: Does the name 'Plus' indicate a higher dose of the main ingredient?

The term 'Plus' in this type of medicine typically indicates that the product is a fixed-dose combination. This means it contains the primary ingredient (Ibuprofen) plus a second active ingredient (Codeine), rather than indicating a higher dose of the first ingredient alone.

---

Q: What are the signs of an allergic reaction to Brufen Plus?

Official warnings state that signs of a serious allergic reaction, or hypersensitivity, may include hives, swelling of the face or throat, difficulty breathing (asthma), or blisters. These severe reactions have been reported, especially in people sensitive to aspirin.

---

Q: Do studies support the combination of ingredients being more effective than ibuprofen alone?

The combination is based on the principle of combining a peripheral and a central analgesic mechanism to achieve a comprehensive approach to pain relief. This dual approach is intended to provide a synergistic effect, which is a recognized strategy for managing moderate to severe pain.

---

Q: What happens if I accidentally take more Brufen Plus than described in the patient leaflet?

Overdose symptoms related to the opioid component can include blue lips or skin (cyanosis), extremely slow or shallow breathing, and extreme drowsiness or coma. Official warnings state that overdose can be fatal and that patients experiencing these symptoms require immediate medical attention.

---

Q: Is there any research looking at the long-term safety of Brufen Plus?

Regulatory documents indicate that the risk of serious adverse effects, such as gastrointestinal bleeding and cardiovascular events, increases with longer duration of use of the ibuprofen component. Consequently, the product is indicated only for short-term use in official guidance.

---

Q: Is Brufen Plus a narcotic or a controlled substance?

The medicine is classified as an opioid due to the codeine component. It is listed as a Schedule 4: Prescription Only Medicine in some jurisdictions and carries warnings regarding the risk of abuse and misuse.

Official Storage Requirements

Brufen Plus tablets must be stored at a temperature below 30°C and protected from moisture and direct sunlight. To maintain the product's stability and shelf life, the tablets must be kept in their original pack until the time of use. The regulatory documents state that the medicine should be kept out of the sight and reach of children at all times, and official guidance for controlled substances suggests securing it in a locked location.

---

Official Disposal Instructions

Due to the presence of the opioid codeine, specific disposal guidelines are mandated. Unused or expired Brufen Plus should be returned to a pharmacist for disposal or handled through an approved drug take-back program. The medicine must not be disposed of in household rubbish or wastewater unless a take-back option is unavailable. In that case, it should be mixed with an undesirable substance, sealed, and placed in the household trash.